Annual EBITDA
-$22.17 M
-$4.46 M-25.16%
December 31, 2023
Summary
- As of February 12, 2025, GANX annual EBITDA is -$22.17 million, with the most recent change of -$4.46 million (-25.16%) on December 31, 2023.
- During the last 3 years, GANX annual EBITDA has fallen by -$18.70 million (-538.91%).
- GANX annual EBITDA is now -2057.42% below its all-time high of -$1.03 million, reached on December 31, 2018.
Performance
GANX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$4.44 M
+$3.72 M+45.64%
September 30, 2024
Summary
- As of February 12, 2025, GANX quarterly EBITDA is -$4.44 million, with the most recent change of +$3.72 million (+45.64%) on September 30, 2024.
- Over the past year, GANX quarterly EBITDA has dropped by -$53.70 thousand (-1.23%).
- GANX quarterly EBITDA is now -769.72% below its all-time high of -$510.20 thousand, reached on March 31, 2020.
Performance
GANX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$21.34 M
+$427.20 K+1.96%
September 30, 2024
Summary
- As of February 12, 2025, GANX TTM EBITDA is -$21.34 million, with the most recent change of +$427.20 thousand (+1.96%) on September 30, 2024.
- Over the past year, GANX TTM EBITDA has increased by +$829.20 thousand (+3.74%).
- GANX TTM EBITDA is now -4082.73% below its all-time high of -$510.20 thousand, reached on March 31, 2020.
Performance
GANX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
GANX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -25.2% | -1.2% | +3.7% |
| 3 y3 years | -538.9% | -38.5% | -54.5% |
| 5 y5 years | -2057.4% | -38.5% | -54.5% |
GANX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -60.5% | at low | -38.5% | +45.6% | -54.5% | +4.4% |
| 5 y | 5-year | -957.0% | at low | -769.7% | +45.6% | -4082.7% | +4.4% |
| alltime | all time | -2057.4% | at low | -769.7% | +45.6% | -4082.7% | +4.4% |
Gain Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$4.44 M(-45.6%) | -$21.34 M(-2.0%) |
| Jun 2024 | - | -$8.16 M(+87.3%) | -$21.77 M(+2.1%) |
| Mar 2024 | - | -$4.36 M(-0.6%) | -$21.32 M(-3.8%) |
| Dec 2023 | -$22.17 M(+25.2%) | -$4.38 M(-9.9%) | -$22.17 M(-0.7%) |
| Sep 2023 | - | -$4.86 M(-36.9%) | -$22.33 M(+0.6%) |
| Jun 2023 | - | -$7.71 M(+48.0%) | -$22.20 M(+13.0%) |
| Mar 2023 | - | -$5.21 M(+14.7%) | -$19.64 M(+10.9%) |
| Dec 2022 | -$17.71 M(+28.3%) | -$4.54 M(-4.0%) | -$17.71 M(+8.2%) |
| Sep 2022 | - | -$4.73 M(-8.2%) | -$16.37 M(+0.6%) |
| Jun 2022 | - | -$5.16 M(+57.2%) | -$16.27 M(+11.2%) |
| Mar 2022 | - | -$3.28 M | -$14.63 M |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$13.81 M(+298.0%) | - | - |
| Dec 2021 | - | -$3.20 M(-30.8%) | -$13.81 M(+13.0%) |
| Sep 2021 | - | -$4.63 M(+31.9%) | -$12.22 M(+45.4%) |
| Jun 2021 | - | -$3.51 M(+42.6%) | -$8.41 M(+55.0%) |
| Mar 2021 | - | -$2.46 M(+52.7%) | -$5.42 M(+56.3%) |
| Dec 2020 | -$3.47 M(+65.4%) | - | - |
| Dec 2020 | - | -$1.61 M(+97.5%) | -$3.47 M(+86.8%) |
| Sep 2020 | - | -$816.70 K(+54.0%) | -$1.86 M(+78.5%) |
| Jun 2020 | - | -$530.20 K(+3.9%) | -$1.04 M(+103.9%) |
| Mar 2020 | - | -$510.20 K | -$510.20 K |
| Dec 2019 | -$2.10 M(+104.1%) | - | - |
| Dec 2018 | -$1.03 M | - | - |
FAQ
- What is Gain Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Gain Therapeutics?
- What is Gain Therapeutics annual EBITDA year-on-year change?
- What is Gain Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Gain Therapeutics?
- What is Gain Therapeutics quarterly EBITDA year-on-year change?
- What is Gain Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Gain Therapeutics?
- What is Gain Therapeutics TTM EBITDA year-on-year change?
What is Gain Therapeutics annual EBITDA?
The current annual EBITDA of GANX is -$22.17 M
What is the all time high annual EBITDA for Gain Therapeutics?
Gain Therapeutics all-time high annual EBITDA is -$1.03 M
What is Gain Therapeutics annual EBITDA year-on-year change?
Over the past year, GANX annual EBITDA has changed by -$4.46 M (-25.16%)
What is Gain Therapeutics quarterly EBITDA?
The current quarterly EBITDA of GANX is -$4.44 M
What is the all time high quarterly EBITDA for Gain Therapeutics?
Gain Therapeutics all-time high quarterly EBITDA is -$510.20 K
What is Gain Therapeutics quarterly EBITDA year-on-year change?
Over the past year, GANX quarterly EBITDA has changed by -$53.70 K (-1.23%)
What is Gain Therapeutics TTM EBITDA?
The current TTM EBITDA of GANX is -$21.34 M
What is the all time high TTM EBITDA for Gain Therapeutics?
Gain Therapeutics all-time high TTM EBITDA is -$510.20 K
What is Gain Therapeutics TTM EBITDA year-on-year change?
Over the past year, GANX TTM EBITDA has changed by +$829.20 K (+3.74%)